Treating patients with 'wake-up' stroke: The experience of the AbESTT-II trial

Stroke

Volumn 39, Issue 12, 2008, Pages 3277-3282

  Adams Jr , Harold P ^a,b   Leira, Enrique C ^a   Torner, James C ^b   Barnathan, Elliot ^c   Padgett, Lakshmi ^c   Effron, Mark B ^d   Hacke, Werner ^e  

^a Department of Neurology ^*  (United States)

^b UNIVERSITY OF IOWA   (United States)

^c CENTOCOR INC   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; PLACEBO; FIBRINOLYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; REPERFUSION; STROKE; TREATMENT RESPONSE; WAKE UP STROKE; WAKEFULNESS; BLEEDING; CHEMICALLY INDUCED DISORDER; CIRCADIAN RHYTHM; COMORBIDITY; COMPARATIVE STUDY; FIBRINOLYTIC THERAPY; MIDDLE AGED; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CEREBRAL HEMORRHAGE; CIRCADIAN RHYTHM; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; REPERFUSION; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 58149345074     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.508853     Document Type: Article

References (10)

1. California Actue Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology. 2005;64:654-659.
2. Fink JN, Kumar S, Horkan C, Linfante I, Selim MH, Caplan LR, Schlaug G. The stroke patient who woke up: clinical and radiological features, including diffusion and perfusion MRI. Stroke. 2002;33:988-993.
3. Serena J, Davalos A, Segura T, Mostacero E, Castillo J. Stroke on awakening: looking for a more rational management. Cerebrovasc Dis. 2003;16:128-133.
4. Nadeau JO, Fang J, Kapral MK, Silver FL, Hill MD, Registry of the Canadian Stroke Network. Outcome after stroke upon awakening. Can J Neurol Sci. 2005;32:232-236.
5. Boode BS, Welzen V, van Oostenbrugge RJ. Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc Dis. 2006;23:294-298.
6. Todo K, Moriwaki H, Saito K, Tanaka M, Oe H, Naritomi H. Early CT findings in unknown-onset and wake-up strokes. Cerebrovasc Dis. 2006; 21:367-371.
7. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke. 2000;31:601- 609.
8. Adams HP Jr, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan E, Hacke W for the AbESTT II investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke results of an international phase III trial. Stroke. 2007;39:87-99.
9. Adams HP Jr, Leclerc JR, Bluhmki E, Clarke W, Hansen MD, Hacke W. Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis. 2004;18:124-129.
10. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke. Results of a randomized phase 2 trial. Stroke. 2005;36:880-890.